ESOPJun 12, 2026, 04:32 PM
Definium Therapeutics Shareholders Approve 5M Share Increase for Equity Plan
AI Summary
Definium Therapeutics, Inc. shareholders approved an amendment to the 2025 Equity Incentive Plan at its 2026 Annual General and Special Meeting, increasing the common shares available for issuance by 5,000,000. Additionally, seven director nominees were elected to the Board of Directors, and KPMG LLP was appointed as the independent registered public accounting firm until the 2027 Annual Meeting.
Key Highlights
- Shareholders approved an amendment to Definium Therapeutics' 2025 Equity Incentive Plan.
- The amendment increases the number of common shares available for issuance by 5,000,000.
- The Equity Plan Amendment was approved with 58,149,028 votes For.
- Seven director nominees were elected to the Board, with votes ranging from 60,056,178 to 62,931,294.
- KPMG LLP was appointed as the independent auditor with 78,579,054 votes For.
- Approximately 72% of Common Shares (78,673,592) were present or represented at the Annual Meeting.
Price Impact
More from DFTX